Skip to main content
Top
Published in: Cardiovascular Diabetology 1/2005

Open Access 01-12-2005 | Case Report

Isolated low high density lipoprotein-cholesterol (HDL-C): implications of global risk reduction. Case report and systematic scientific review

Authors: Melvin R Hayden, Suresh C Tyagi

Published in: Cardiovascular Diabetology | Issue 1/2005

Login to get access

Abstract

Background

The importance of low high-density lipoprotein cholesterol (HDL-C), elevated non HDL-C (as part of the metabolic syndrome, prediabetes, and type 2 diabetes mellitus), and an isolated low HDL-C is rapidly emerging. The antiatherosclerotic roles of reverse cholesterol transport and the pleiotropic antioxidant – anti-inflammatory mechanistic effects of HDL-C are undergoing rapid exponential growth.

Case presentation

In 1997 a 53-year-old Caucasian male presented with a lipoprotein profile of many years duration with an isolated low HDL-C and uric acid levels in the upper quintile of normal. He developed an acute myocardial infarction involving the right coronary artery and had percutaneous transluminal coronary angioplasty with stenting of this lesion. He also demonstrated a non-critical non-flow limiting lesion of the proximal left anterior descending coronary artery at the time of this evaluation.
Following a program of global risk reduction this patient has done well over the past 7 years and remains free of any clinical signs and symptoms of atherosclerosis. His HDL-C and uric acid levels are currently in the normal physiological range.

Conclusion

Low HDL-C and isolated low HDL-C constitute an important risk factor for atherosclerosis. Therapies that lead to a return to normal physiologic range of HDL-C may result in the delay of atherosclerotic progression.
Appendix
Available only for authorised users
Literature
1.
go back to reference Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults: Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA. 2001, 285 (19): 2486-2497. 10.1001/jama.285.19.2486.CrossRef Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults: Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA. 2001, 285 (19): 2486-2497. 10.1001/jama.285.19.2486.CrossRef
2.
go back to reference Hayden MR, Tyagi SC: Intimal redox stress: Accelerated atherosclerosis in metabolic syndrome and type 2 diabetes mellitus. Atheroscleropathy. Cardiovasc Diabetol. 2002, 1 (1): 3-10.1186/1475-2840-1-3.PubMedCentralCrossRefPubMed Hayden MR, Tyagi SC: Intimal redox stress: Accelerated atherosclerosis in metabolic syndrome and type 2 diabetes mellitus. Atheroscleropathy. Cardiovasc Diabetol. 2002, 1 (1): 3-10.1186/1475-2840-1-3.PubMedCentralCrossRefPubMed
3.
go back to reference Hayden MR, Tyagi SC: Is type 2 diabetes mellitus a vascular disease (atheroscleropathy) with hyperglycemia a late manifestation? The role of NOS, NO, and redox stress. Cardiovasc Diabetol. 2003, 2 (1): 2-10.1186/1475-2840-2-2.PubMedCentralCrossRefPubMed Hayden MR, Tyagi SC: Is type 2 diabetes mellitus a vascular disease (atheroscleropathy) with hyperglycemia a late manifestation? The role of NOS, NO, and redox stress. Cardiovasc Diabetol. 2003, 2 (1): 2-10.1186/1475-2840-2-2.PubMedCentralCrossRefPubMed
4.
go back to reference Hayden MR, Tyagi SC: Vasa vasorum in plaque angiogenesis, metabolic syndrome, type 2 diabetes mellitus, and atheroscleropathy: a malignant transformation. Cardiovasc Diabetol. 2004, 3 (1): 1-10.1186/1475-2840-3-1.PubMedCentralCrossRefPubMed Hayden MR, Tyagi SC: Vasa vasorum in plaque angiogenesis, metabolic syndrome, type 2 diabetes mellitus, and atheroscleropathy: a malignant transformation. Cardiovasc Diabetol. 2004, 3 (1): 1-10.1186/1475-2840-3-1.PubMedCentralCrossRefPubMed
5.
go back to reference Hayden MR: Global risk reduction of reactive oxygen species in metabolic syndrome, type 2 diabetes mellitus, and atheroscleropathy. Medical Hypothesis and Research. 2004, 1 (2/3): 171-185. Hayden MR: Global risk reduction of reactive oxygen species in metabolic syndrome, type 2 diabetes mellitus, and atheroscleropathy. Medical Hypothesis and Research. 2004, 1 (2/3): 171-185.
6.
go back to reference Miller NE, Thelle DS, Forde OH, Mjos OD: The Tromso heart-study. High-density lipoprotein and coronary heart-disease: a prospective case-control study. Lancet. 1977, 1 (8019): 965-968. 10.1016/S0140-6736(77)92274-7.CrossRefPubMed Miller NE, Thelle DS, Forde OH, Mjos OD: The Tromso heart-study. High-density lipoprotein and coronary heart-disease: a prospective case-control study. Lancet. 1977, 1 (8019): 965-968. 10.1016/S0140-6736(77)92274-7.CrossRefPubMed
7.
go back to reference Castelli WP, Garrison RJ, Wilson PW, Abbott RD, Kalousdian S, Kannel WB: Incidence of coronary heart disease and lipoprotein cholesterol levels. The Framingham Study. JAMA. 1986, 256 (20): 2835-2838. 10.1001/jama.256.20.2835.CrossRefPubMed Castelli WP, Garrison RJ, Wilson PW, Abbott RD, Kalousdian S, Kannel WB: Incidence of coronary heart disease and lipoprotein cholesterol levels. The Framingham Study. JAMA. 1986, 256 (20): 2835-2838. 10.1001/jama.256.20.2835.CrossRefPubMed
8.
go back to reference Wilson PW, Abbott RD, Castelli WP: High density lipoprotein cholesterol and mortality. The Framingham Heart Study. Arteriosclerosis. 1988, 8 (6): 737-741.CrossRefPubMed Wilson PW, Abbott RD, Castelli WP: High density lipoprotein cholesterol and mortality. The Framingham Heart Study. Arteriosclerosis. 1988, 8 (6): 737-741.CrossRefPubMed
9.
go back to reference Miller M: Raising an isolated low HDL-C level: why, how, and when?. Cleve Clin J Med. 2003, 70 (6): 553-560.CrossRefPubMed Miller M: Raising an isolated low HDL-C level: why, how, and when?. Cleve Clin J Med. 2003, 70 (6): 553-560.CrossRefPubMed
10.
go back to reference Goldbourt U, Yaari S, Medalie JH: Isolated low HDL cholesterol as a risk factor for coronary heart disease mortality. A 21-year follow-up of 8000 men. Arterioscler Thromb Vasc Biol. 1997, 17 (1): 107-113.CrossRefPubMed Goldbourt U, Yaari S, Medalie JH: Isolated low HDL cholesterol as a risk factor for coronary heart disease mortality. A 21-year follow-up of 8000 men. Arterioscler Thromb Vasc Biol. 1997, 17 (1): 107-113.CrossRefPubMed
11.
go back to reference Probst MC, Thumann H, Aslanidis C, Langmann T, Buechler C, Patsch W, Baralle FE, Dallinga-Thie GM, Geisel J, Keller C, Menys VC, Schmitz G: Screening for functional sequence variations and mutations in ABCA1. Atherosclerosis. 2004, 175 (2): 269-279. 10.1016/j.atherosclerosis.2004.02.019.CrossRefPubMed Probst MC, Thumann H, Aslanidis C, Langmann T, Buechler C, Patsch W, Baralle FE, Dallinga-Thie GM, Geisel J, Keller C, Menys VC, Schmitz G: Screening for functional sequence variations and mutations in ABCA1. Atherosclerosis. 2004, 175 (2): 269-279. 10.1016/j.atherosclerosis.2004.02.019.CrossRefPubMed
12.
go back to reference Zheng L, Nukuna B, Brennan ML, Sun M, Goormastic M, Settle M, Schmitt D, Fu X, Thomson L, Fox PL, Ischiropoulos H, Smith JD, Kinter M, Hazen SL: Apolipoprotein A-I is a selective target for myeloperoxidase-catalyzed oxidation and functional impairment in subjects with cardiovascular disease. J Clin Invest. 2004, 114 (4): 529-541. 10.1172/JCI200421109.PubMedCentralCrossRefPubMed Zheng L, Nukuna B, Brennan ML, Sun M, Goormastic M, Settle M, Schmitt D, Fu X, Thomson L, Fox PL, Ischiropoulos H, Smith JD, Kinter M, Hazen SL: Apolipoprotein A-I is a selective target for myeloperoxidase-catalyzed oxidation and functional impairment in subjects with cardiovascular disease. J Clin Invest. 2004, 114 (4): 529-541. 10.1172/JCI200421109.PubMedCentralCrossRefPubMed
13.
go back to reference Qujeq D, Omran TS, Hosini L: Correlation between total homocysteine, low-density lipoprotein cholesterol and high-density lipoprotein cholesterol in the serum of patients with myocardial infarction. Clin Biochem. 2001, 34 (2): 97-101. 10.1016/S0009-9120(01)00187-4.CrossRefPubMed Qujeq D, Omran TS, Hosini L: Correlation between total homocysteine, low-density lipoprotein cholesterol and high-density lipoprotein cholesterol in the serum of patients with myocardial infarction. Clin Biochem. 2001, 34 (2): 97-101. 10.1016/S0009-9120(01)00187-4.CrossRefPubMed
14.
go back to reference Hayden MR, Tyagi SC: Uric acid: A new look at an old risk marker for cardiovascular disease, metabolic syndrome, and type 2 diabetes mellitus: The urate redox shuttle. Nutr Metab (Lond). 2004, 1 (1): 10-10.1186/1743-7075-1-10.CrossRef Hayden MR, Tyagi SC: Uric acid: A new look at an old risk marker for cardiovascular disease, metabolic syndrome, and type 2 diabetes mellitus: The urate redox shuttle. Nutr Metab (Lond). 2004, 1 (1): 10-10.1186/1743-7075-1-10.CrossRef
15.
go back to reference Yusuf S, Hawken S, Ounpuu S, Dans T, Avezum A, Lanas F, McQueen M, Budaj A, Pais P, Varigos J, Lisheng L, INTERHEART Study Investigators: Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet. 2004, 364 (9438): 937-952. 10.1016/S0140-6736(04)17018-9.CrossRefPubMed Yusuf S, Hawken S, Ounpuu S, Dans T, Avezum A, Lanas F, McQueen M, Budaj A, Pais P, Varigos J, Lisheng L, INTERHEART Study Investigators: Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet. 2004, 364 (9438): 937-952. 10.1016/S0140-6736(04)17018-9.CrossRefPubMed
16.
17.
go back to reference Ou J, Ou Z, Jones DW, Holzhauer S, Hatoum OA, Ackerman AW, Weihrauch DW, Gutterman DD, Guice K, Oldham KT, Hillery CA, Pritchard KA: L-4F, an apolipoprotein A-1 mimetic, dramatically improves vasodilation in hypercholesterolemia and sickle cell disease. Circulation. 2003, 107 (18): 2337-2341. 10.1161/01.CIR.0000070589.61860.A9.CrossRefPubMed Ou J, Ou Z, Jones DW, Holzhauer S, Hatoum OA, Ackerman AW, Weihrauch DW, Gutterman DD, Guice K, Oldham KT, Hillery CA, Pritchard KA: L-4F, an apolipoprotein A-1 mimetic, dramatically improves vasodilation in hypercholesterolemia and sickle cell disease. Circulation. 2003, 107 (18): 2337-2341. 10.1161/01.CIR.0000070589.61860.A9.CrossRefPubMed
18.
go back to reference van der Steeg W, Kuivenhoven J, Klerkx A, Boekholdt S, Hovingh G, Kastelein J: Role of CETP inhibitors in the treatment of dyslipidemia. Curr Opin Lipidol. 2004, 15 (6): 631-636. 10.1097/00041433-200412000-00002.CrossRefPubMed van der Steeg W, Kuivenhoven J, Klerkx A, Boekholdt S, Hovingh G, Kastelein J: Role of CETP inhibitors in the treatment of dyslipidemia. Curr Opin Lipidol. 2004, 15 (6): 631-636. 10.1097/00041433-200412000-00002.CrossRefPubMed
19.
go back to reference Kino T, Chrousos GP: Combating Atherosclerosis With LXR{alpha} And PPAR{alpha} Agonists: Is Rational Multitargeted Polypharmacy the Future of Therapeutics in Complex Diseases?. Mol Interv. 2004, 4 (5): 254-257. 10.1124/mi.4.5.5.CrossRefPubMed Kino T, Chrousos GP: Combating Atherosclerosis With LXR{alpha} And PPAR{alpha} Agonists: Is Rational Multitargeted Polypharmacy the Future of Therapeutics in Complex Diseases?. Mol Interv. 2004, 4 (5): 254-257. 10.1124/mi.4.5.5.CrossRefPubMed
20.
go back to reference 150th anniversary of John Snow and the pump handle. JAMA. 2004, 292: 1950-10.1001/jama.292.16.1950. 150th anniversary of John Snow and the pump handle. JAMA. 2004, 292: 1950-10.1001/jama.292.16.1950.
21.
go back to reference CDC: 150th Anniversary of John Snow and the pump handle. MMWR Morb Mortal Wkly Rep. 2004, 53 (34): 783. CDC: 150th Anniversary of John Snow and the pump handle. MMWR Morb Mortal Wkly Rep. 2004, 53 (34): 783.
Metadata
Title
Isolated low high density lipoprotein-cholesterol (HDL-C): implications of global risk reduction. Case report and systematic scientific review
Authors
Melvin R Hayden
Suresh C Tyagi
Publication date
01-12-2005
Publisher
BioMed Central
Published in
Cardiovascular Diabetology / Issue 1/2005
Electronic ISSN: 1475-2840
DOI
https://doi.org/10.1186/1475-2840-4-1

Other articles of this Issue 1/2005

Cardiovascular Diabetology 1/2005 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine